Clinical Pharmacology in Drug Development

Scope & Guideline

Empowering professionals with cutting-edge pharmacological insights.

Introduction

Welcome to the Clinical Pharmacology in Drug Development information hub, where our guidelines provide a wealth of knowledge about the journal’s focus and academic contributions. This page includes an extensive look at the aims and scope of Clinical Pharmacology in Drug Development, highlighting trending and emerging areas of study. We also examine declining topics to offer insight into academic interest shifts. Our curated list of highly cited topics and recent publications is part of our effort to guide scholars, using these guidelines to stay ahead in their research endeavors.
LanguageEnglish
ISSN2160-7648
PublisherWILEY
Support Open AccessNo
CountryUnited States
TypeJournal
Convergefrom 2012 to 2024
AbbreviationCLIN PHARM DRUG DEV / Clin. Pharmacol. Drug Dev.
Frequency6 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
Address111 RIVER ST, HOBOKEN 07030-5774, NJ

Aims and Scopes

The journal 'Clinical Pharmacology in Drug Development' focuses on advancing the field of clinical pharmacology, particularly through the evaluation of drug pharmacokinetics, bioequivalence, safety, and efficacy in various populations. It emphasizes studies that contribute to drug development processes and regulatory science, with a strong emphasis on methodological rigor and innovative approaches.
  1. Pharmacokinetics and Pharmacodynamics:
    Research that explores the absorption, distribution, metabolism, and excretion of drugs, alongside their biological effects, is a core focus. This includes studies on drug-drug interactions and the impact of genetic factors on drug response.
  2. Bioequivalence Studies:
    The journal frequently publishes studies assessing the bioequivalence of generic and branded drugs, which are critical for regulatory approvals and market access.
  3. Safety and Tolerability Assessments:
    A significant portion of the research is dedicated to evaluating the safety profiles of new drugs, including adverse effects and tolerability in diverse populations.
  4. Population Pharmacokinetics:
    Studies that utilize population pharmacokinetic modeling to analyze drug behavior in specific patient groups, including those with comorbidities or differing ethnic backgrounds, are highlighted to enhance personalized medicine.
  5. Phase I Clinical Trials:
    The journal emphasizes research from Phase I trials, which are essential for understanding the initial safety, tolerability, and pharmacokinetic profiles of new therapeutic agents.
  6. Innovative Drug Development Methodologies:
    The journal encourages submissions that explore new methodologies in drug development, including model-informed approaches and adaptive trial designs.
The journal has witnessed emerging themes that reflect the evolving landscape of drug development and clinical pharmacology. These trends indicate a shift towards precision medicine and innovative therapeutic strategies.
  1. Personalized Medicine Approaches:
    There is an increasing emphasis on studies that explore personalized medicine, particularly how individual genetic makeup influences drug response and safety, reflecting a broader trend in healthcare towards tailored therapies.
  2. Innovations in Drug Delivery Systems:
    Research focusing on novel drug delivery systems, including sustained-release formulations and targeted delivery mechanisms, has gained traction, highlighting advancements in improving drug efficacy and patient compliance.
  3. Real-World Evidence and Post-Marketing Surveillance:
    The journal is increasingly publishing studies that utilize real-world evidence to assess drug performance post-approval, emphasizing the importance of understanding drug effects in everyday clinical practice.
  4. Complex Drug Interactions:
    The complexity of drug-drug interactions, especially involving polypharmacy in older populations or patients with comorbid conditions, is becoming a more prominent area of research, reflecting the realities of modern healthcare.
  5. Evolving Regulatory Science:
    There is a growing interest in the regulatory aspects of drug development, including submissions that discuss the implications of new regulations on clinical trial designs and drug approval processes.

Declining or Waning

While the journal maintains a strong focus on pharmacokinetics and drug development, certain areas of research have seen a reduction in prominence over recent years, reflecting shifts in scientific interest and regulatory priorities.
  1. Traditional Drug Formulations:
    There has been a noticeable decline in studies focused solely on traditional drug formulations without considering innovative delivery systems or combinations. The shift towards more complex formulations and combination therapies is evident.
  2. Non-Clinical Studies:
    Research that primarily focuses on non-clinical or preclinical studies has decreased, as the journal emphasizes clinical data and results from human trials.
  3. Fixed-Dose Combinations without Novel Insights:
    Publications that discuss fixed-dose combinations without providing new insights into their pharmacokinetic profiles or novel therapeutic outcomes have become less frequent, as the field moves towards more innovative combinations.
  4. Pharmacogenomics Studies:
    Although pharmacogenomics remains important, the specific focus on genetic polymorphisms affecting pharmacokinetics has seen a decline, possibly due to the broader integration of such analyses into standard pharmacokinetic studies.

Similar Journals

AAPS Journal

Leading the Charge in Open Access Pharmaceutical Research.
Publisher: SPRINGERISSN: 1550-7416Frequency: 1 issue/year

AAPS Journal, published by Springer in the United States, is a leading peer-reviewed journal dedicated to the advancement of research in the field of Pharmaceutical Sciences. With an impressive Q1 rank in its category and a position within the 81st percentile of Scopus rankings, it serves as a vital resource for researchers and professionals seeking to disseminate impactful findings and innovative methodologies. The journal publishes high-quality original research, review articles, and technical reports aimed at addressing the multifaceted challenges in pharmacology, toxicology, and pharmaceutics. Operating under an Open Access model, AAPS Journal ensures broad dissemination of knowledge, contributing to the enhanced visibility and accessibility of research outputs. With a publication window spanning from 1999 to 2024, it continues to shape the future of pharmaceutical research and its applications. Researchers, students, and industry professionals will find a valuable repository of cutting-edge knowledge in this esteemed journal.

Advances in Pharmacological and Pharmaceutical Sciences

Exploring Innovations in Pharmaceutical Research.
Publisher: HINDAWI LTDISSN: 2633-4682Frequency: 1 issue/year

Advances in Pharmacological and Pharmaceutical Sciences is a premier open-access journal published by Hindawi Ltd. based in the United Kingdom. Established in 2020, the journal swiftly garnered attention for its commitment to disseminating high-quality research in the realms of pharmacology, toxicology, and pharmaceutical sciences. It holds a commendable impact with notable quartile rankings, including Q2 in both Organic Chemistry and Pharmacology, indicating its importance within these disciplines. By embracing an open-access model, the journal ensures that research findings are widely available, promoting increased visibility and collaboration among researchers, professionals, and students globally. With an ongoing convergence of insights projected through 2024, Advances in Pharmacological and Pharmaceutical Sciences aims to address critical issues and advancements in drug development and therapeutic practices, making it an invaluable resource for those at the forefront of scientific inquiry in pharmacology and related fields.

PHARMACIA

Elevating research in pharmaceutical sciences to global heights.
Publisher: PENSOFT PUBLISHERSISSN: 0428-0296Frequency: 4 issues/year

PHARMACIA is a distinguished open-access journal, published by PENSOFT PUBLISHERS, that has been a pivotal platform for advancing the field of pharmaceutical sciences since 2007. This journal, with ISSN 0428-0296 and E-ISSN 2603-557X, is based in Bulgaria and continues to publish high-quality research and reviews relevant to pharmacy, pharmacology, and toxicology. Recognized in the Q3 category for Pharmaceutical Sciences and Pharmacology (medical), as well as Q2 in Pharmacy according to the latest rankings, PHARMACIA is celebrated for its commitment to fostering knowledge dissemination and innovation in drug development, therapeutic approaches, and pharmacological research. With a Scopus rank of #17 in Pharmacy and recognition in various health professions, the journal attracts contributions from researchers, professionals, and students seeking to impact the pharmaceutical landscape. Its convenient open-access format ensures that articles are readily available to a global audience, encouraging collaboration and advancement in the life sciences.

CPT-Pharmacometrics & Systems Pharmacology

Bridging the gap between pharmacology and systems science.
Publisher: WILEYISSN: 2163-8306Frequency: 12 issues/year

CPT-Pharmacometrics & Systems Pharmacology, published by WILEY, is a leading open access journal dedicated to advancing the fields of pharmacometrics and systems pharmacology. Since its inception in 2012, it has established itself as a vital resource for researchers and practitioners, boasting a remarkable impact factor and occupying prestigious Q1 quartiles in categories such as Cardiology and Cardiovascular Medicine, Modeling and Simulation, and Pharmacology (Medical). The journal covers a broad spectrum of topics aimed at enhancing the understanding of drug development, efficacy, and patient safety through innovative modeling and simulation approaches. With its consistent ranking in the top tiers of its field, CPT-Pharmacometrics & Systems Pharmacology provides invaluable insights and fosters scholarly dialogue among its audience, including researchers, educators, and students. The journal is accessible to all, promoting knowledge dissemination and collaborative growth in the pharmacology community.

INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS

Empowering healthcare through cutting-edge pharmacological studies.
Publisher: DUSTRI-VERLAG DR KARL FEISTLEISSN: 0946-1965Frequency: 12 issues/year

INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, published by DUSTRI-VERLAG DR KARL FEISTLE in Germany, is a vital scholarly platform dedicated to advancing the field of pharmacology through rigorous research and innovative therapeutic strategies. Established in 1994, this journal has maintained its relevance in the evolving landscape of clinical pharmacology, achieving a Q3 rank in both general and medical pharmacology categories as of 2023. With an ISSN of 0946-1965, it is positioned as an essential resource for researchers, healthcare professionals, and students seeking to enhance their understanding of drug therapy and pharmacological applications. Though it currently does not offer open access, its comprehensive scope covers a wide array of topics within pharmacology, promising to contribute significantly to scientific discussions and knowledge dissemination from 1994 to 2024. Whether you are looking for the latest studies or historical insights, the journal remains a fixture for anyone invested in the pharmacological sciences.

International Journal of Pharmacology

Exploring the Depths of Drug Actions and Interactions
Publisher: ASIAN NETWORK SCIENTIFIC INFORMATION-ANSINETISSN: 1811-7775Frequency: 8 issues/year

Welcome to the International Journal of Pharmacology, a key publication in the field of pharmacology, published by ASIAN NETWORK SCIENTIFIC INFORMATION (ANSINET). Since its inception in 2006, this journal has provided a vital platform for researchers and professionals to disseminate their findings and insights in pharmacology, toxicology, and pharmaceutics. Despite recent discontinuation in Scopus coverage, the journal's dedication to fostering scientific dialogue continues to attract contributions from esteemed scholars globally. With an **ISSN of 1811-7775** and **E-ISSN of 1812-5700**, the journal seeks to bridge the gap between laboratory research and clinical application, promoting a deeper understanding of drug actions and interactions. Although it operates under traditional access options, the relevance of its published studies to ongoing pharmacological research remains significant.

DARU-Journal of Pharmaceutical Sciences

Empowering researchers to shape the future of medicine.
Publisher: SPRINGER INT PUBL AGISSN: Frequency: 2 issues/year

DARU-Journal of Pharmaceutical Sciences is a leading peer-reviewed journal published by SPRINGER INT PUBL AG that focuses on the dynamic and rapidly evolving fields of pharmaceutical sciences, including drug discovery, pharmacology, and toxicology. With an impressive Q2 ranking in both Drug Discovery and Miscellaneous Medicine categories for 2023, this journal stands out as a vital resource for researchers, professionals, and students alike, offering a platform for significant contributions to the scientific community. Covering a comprehensive scope from 2000 to 2024 and indexed by Scopus, the journal ranks within the top percentile in its field, with a ranking of #66/313 in Pharmacology and #34/157 in Drug Discovery, reaffirming its impact and relevance. The journal promotes open access to foster widespread dissemination of knowledge in pharmaceutical sciences, ultimately aiming to bridge the gap between research and clinical applications. For those looking to stay at the forefront of pharmaceutical innovation, DARU represents an invaluable connection to the latest studies and breakthrough findings.

EXPERT OPINION ON INVESTIGATIONAL DRUGS

Connecting Researchers with Cutting-edge Discoveries
Publisher: TAYLOR & FRANCIS LTDISSN: 1354-3784Frequency: 12 issues/year

Expert Opinion on Investigational Drugs, published by Taylor & Francis Ltd, is a premier journal dedicated to the dissemination of high-quality, peer-reviewed research in the fields of pharmacology and medicine. As an integral part of the scientific community since its inception in 1994, this journal has established itself as a leading source of insightful analysis and expert commentary on emerging drug therapies, providing invaluable resources for researchers, clinicians, and healthcare professionals. With an impressive impact factor and ranking in the top quartile across multiple pharmacological categories, it remains a vital platform for discussing innovative drug developments and their clinical applications. Though it operates on a subscription basis, Expert Opinion on Investigational Drugs is crucial for anyone involved in pharmacological research and the drug development process, positioning itself at the forefront of medical advancements and offering critical insights into the rapid evolution of investigational therapies.

BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY

Exploring Innovations in Drug Action and Safety
Publisher: WILEYISSN: 1742-7835Frequency: 12 issues/year

BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, published by WILEY, serves as a vital resource in the fields of medicine, pharmacology, and toxicology. With an ISSN of 1742-7835 and E-ISSN 1742-7843, this journal has established a robust reputation, reflected in its Q2 classification across its categories in 2023. It aims to disseminate high-quality research and reviews that bridge the gap between basic scientific findings and clinical applications. Operating from the United States with an address at 111 RIVER ST, HOBOKEN 07030-5774, NJ, this journal focuses on the intersection of drug action and toxicity, making it an essential platform for researchers, healthcare professionals, and students. With a converged publication timeline from 2004 to 2024, BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY continues to make significant contributions to understanding pharmacological treatments and toxicological challenges. Open access options are available to broaden the reach and impact of its published work.

TROPICAL JOURNAL OF PHARMACEUTICAL RESEARCH

Pioneering research at the intersection of science and care.
Publisher: PHARMACOTHERAPY GROUPISSN: 1596-5996Frequency: 2 issues/year

Tropical Journal of Pharmaceutical Research is an esteemed open-access platform dedicated to advancing the field of pharmaceutical sciences, published by the Pharmacotherapy Group in Nigeria. With an ISSN of 1596-5996 and open access established since 2002, this journal serves as a critical resource for researchers, professionals, and students seeking to disseminate and access high-quality research in both pharmaceutical science and pharmacology. Despite its ranking in the third quartile (Q3) for Pharmaceutical Science and the fourth quartile (Q4) in Pharmacology as of 2023, the journal continues to stand out with its commitment to fostering significant dialogue and innovation in the scientific community. Anchored at the University of Benin, Faculty of Pharmacy, the journal invites contributions that explore novel pharmaceutical research, clinical applications, and drug development, playing a vital role in addressing health challenges that are particularly relevant to tropical regions. Researchers can look forward to publishing their findings in a journal that not only promotes the sharing of knowledge but also enhances the scientific discourse within a rapidly evolving field.